Physician profile
Pablo Anglas
NPI 1033139738
$1,909.37
in general payments reported to CMS, 2019-2025
17 companies · $420 in 2025
The $420 reported for 2025 was more than what 91% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $173 · 2021: $328 · 2022: $240 · 2023: $428 · 2024: $64.93 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $913.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gm Pharmaceuticals, INC. | $437.66 | 2022-2023 | Vanacof |
| Pfizer INC. | $240.54 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $239.78 | 2021 | |
| Glaxosmithkline, LLC. | $225.71 | 2019-2023 | Bexsero |
| Cranial Technologies, INC | $169.77 | 2019-2025 | Doc Band |
| Collegium Pharmaceutical, INC. | $124.99 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $111.21 | 2025 | Qelbree |
| Sanofi Pasteur INC. | $74.18 | 2019-2023 | |
| Cipher Pharmaceuticals US LLC | $66.64 | 2025 | Spinosad, Natroba |
| Phadia US INC. | $56.09 | 2020-2024 | Immunocap |
| Merck Sharp & Dohme LLC | $33.32 | 2022-2023 | Gardasil 9, Vaqta, M-M-R II |
| Mission Pharmacal Company | $26.30 | 2019-2020 | |
| Verrica Pharmaceuticals INC. | $24.80 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $24.30 | 2025 | |
| Hologic Sales and Service, LLC | $21.94 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $17.51 | 2025 | Watchman |
| Allergan, INC. | $14.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Anglas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.